As an Food and Drug Administration–approved compound, pyrimethamine is already being tested in the clinic and has shown activity in the treatment of several STAT3-driven malignancies, including chronic lymphocytic leukemia (10), breast cancer, and intermediate-risk to high-risk myelodysplastic syndrome. The gene discussed is STAT3; the disease is breast carcinoma.